In the above published article by Okumura et al., the authors apologize for errors in the 2nd, 3rd and 4th columns of Table 2. The corrected Table 2 is given below.
Note. BZDs = benzodiazepines; CI = confidence interval; FGAs = first-generation antipsychotics; NGAs = new-generation antidepressants; SGAs = second-generation antipsychotics; TCAs = tricyclic antidepressants.
* p < .05
The following corrections related to Table 2 have also been made to the article:
ABSTRACT (Results)
Results: In 2008–2010, the most prevalently prescribed psychotropic medications to patients with dementia were sedatives-hypnotics (27.3%), antipsychotics (21.3%), antidepressants (11.4%), and mood-stabilizers (2.8%). Between 2002–2004 and 2008–2010, use of second-generation antipsychotics increased from 4.9% to 11.2%, while use of first-generation antipsychotics decreased from 17.4% to 12.1%.
Results: (paragraph 4)
In 2008–2010, the most prescribed psychotropic classes were sedatives-hypnotics (27.3%), antipsychotics (21.3%), antidepressants (11.4%), and mood-stabilizers (2.8%).
Results: (paragraph 5)
Figure 1 shows major results of trends in antipsychotics use between 2002 and 2010. Amongst the antipsychotics, prevalent utilization of SGAs markedly increased from 4.9% to 11.2% (OR 2.95, 95% CI 2.44–3.59), while the use of FGAs declined from 17.4% to 12.1% (OR 0.71, 95% CI 0.62–0.80) between 2002–2004 and 2008–2010.
Results: (paragraph 6)
Amongst the antidepressants, prevalent utilization of NGAs slightly increased from 6.0% to 7.1% (OR 1.36, 95% CI 1.13–1.65), and other antidepressants increased from 3.6% to 3.8% (OR 1.37, 95% CI 1.08–1.75) between 2002–2004 and 2008–2010.
Results: (paragraph 8)
Amongst the sedatives-hypnotics, the most prescribed subclasses were hypnotic BZDs (17.2%), Sedative BZDs (11.9%), z-drugs (7.4%), and other sedatives-hypnotics (1.3%) in 2008–2010. Between 2002–2004 and 2008–2010, the prevalent utilization of z-drugs increased from 4.7% to 7.4% (OR 1.67, 95% CI 1.37–2.04) although use of any BZDs, sedative BZDs, hypnotic BZDs, and other sedatives-hypnotics remained stable.
Discussion (paragraph 1)
Our study yielded six major findings using data collected from outpatients with dementia. First, we observed a 1.1-fold increase in the extensive use of antipsychotics (about 21%) over time.
Discussion (paragraph 3)
We observed a stable non-negligible use of sedative BZDs (12%) over time.
The corrections do not alter the conclusions of this article and the authors regret these errors.